A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer

Clinical trial NCT03809013 · COMPLETED

Trial details

NCT number: NCT03809013
Sponsor: RemeGen Co., Ltd.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Urothelial Carcinoma

Start date: 2019-01-07
Primary completion: 2021-03-04
Enrollment: 64

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.